Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
Commercial arrangement
There is a simple discount patient access scheme for maribavir. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisat...
Kidney transplantation from a living donor, when available, is the treatment of choice for most patients with end stage renal disease, offering optimum patient and graft survival and reduced time on the national transplant waiting list. Living donor transplantation also offers a proportion of complex rec...
Hepatitis B is a common infectious disease that can result in progressive liver damage requiring liver transplantation. Due to the high prevalence of hepatitis B infection worldwide many patients who are transplanted with other solid organs will have either had hepatitis B in the past or have active dise...
The incidence and prevalence of hepatitis E virus (HEV) infection has increased in many developed countries over the last decade. It has also been recognised that HEV infection can persist in immunosuppressed individuals, leading if left untreated to chronic hepatitis and significant liver fibrosis. Tran...
